Tag Archives: antibiotics

Ordering Pharmacist Dosing of Antibiotics

Paragon version 12.x

Antibiotics can be dosed by a clinical pharmacist for all inpatients. Dosing is done through P&T approved protocols.

To order:

  1. Go to Paragon clinician hub
  2. Ordering tab
  3. Order Queue
  4. Search for “antibiotics”
  5. Select RX formulary oral & injectable antibiotics

Please DO NOT order in any of the following

  1. As a miscellaneous nursing order
  2. As a message to the pharmacist
  3. In the comments section of an antibiotic order

Johns Hopkins ABX Guides

Pharmacy Services has subscribed to Johns Hopkins ABX Guide for use by all associates at Centegra Health System to support our multidisciplinary approach to the Antimicrobial Stewardship Program Clinical Decision Support Tools and Education

Johns Hopkins ABX Guide is a comprehensive web source that provides regularly updated, evidence-based decision resources regarding antibiotics, diagnosis, pathogens, management of infections and vaccines.

Prior to the Guide, CHS did not have a specific detailed resource for antibiotics clinical decision support.

Johns Hopkins ABX Guide may be accessed through Unbound Medicine’s uCentral as follows:

List of antibiotics restricted to ID approval

  • Ceftaroline (TEFLARO) – Non formulary
  • Liposomal Amphotericin (AMBISOME) – Formulary
  • Daptomycin (CUBICIN) – Non formulary
  • Linezolid (ZYVOX) – Formulary
  • Voriconazole (VFEND) – Formulary
  • Imipenem (PRIMAXIN) – Formulary
  • Gancyclovir (CYTOVENE) – Non formulary
  • Tigecycline (TYGACIL) – Non Formulary
  • Doripenem (DORIBAX) – Non Formulary

Antibiotic usage in hospitalized patients

CDC reported in the March 7th 2014 issue of MMWR that based on a 2010 study conducted across the US that upto 30% of non ICU antibiotics used in hospitalized patients are unecessary. The most common overusage of antibiotics was for “UTI” and the use of vancomycin without proven positive cultures. Appropriate usage of antibiotics can reduce the incidence of clostridium difficile infections. [1]

Tygacil safety alert – FDA

Health care professionals should reserve Tygacil for use in situations when alternative treatments are not suitable.

This analysis showed a higher risk of death among patients receiving Tygacil compared to other antibacterial drugs: 2.5% (66/2640) vs. 1.8% (48/2628), respectively. The adjusted risk difference for death was 0.6% with corresponding 95% confidence interval (0.0%, 1.2%). In general, the deaths resulted from worsening infections, complications of infection, or other underlying medical conditions.


Tygacil (tigecycline): Drug Safety Communication – Increased Risk of Death, Sept 27th 2013

FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection

The U.S. Food and Drug Administration (FDA) has required the drug labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious side effect of peripheral neuropathy. This serious nerve damage potentially caused by fluoroquinolones may occur soon after these drugs are taken and may be permanent.

The risk of peripheral neuropathy occurs only with fluoroquinolones that are taken by mouth or by injection. Approved fluoroquinolone drugs include levofloxacin (Levaquin), ciprofloxacin (Cipro), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), and gemifloxacin (Factive). The topical formulations of fluoroquinolones, applied to the ears or eyes, are not known to be associated with this risk.

If a patient develops symptoms of peripheral neuropathy, the fluoroquinolone should be stopped, and the patient should be switched to another, non-fluoroquinolone antibacterial drug, unless the benefit of continued treatment with a fluoroquinolone outweighs the risk.


FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection